A Phase II Study Investigating Fruquintinib plus FOLFIRI as Second-Line Treatment for Participants with Metastatic Colorectal Cancer (mCRC)
Indication: Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer
Trial Number: 07011576
Trial Status: OPEN